Neurocrine Biosciences: Q3 Earnings Insights - Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences NBIX reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM.

Here's what investors need to know about the announcement.

Neurocrine Biosciences beat estimated earnings by 35.0%, reporting an EPS of $1.08 versus an estimate of $0.8.

Revenue was up $91.90 million from the same period last year.

Last quarter the company beat on EPS by $0.25 which was followed by a 8.45% increase in the share price the next day.

Here's a look at Neurocrine Biosciences's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	0.59	0.34	0.52	0.60
EPS Actual	0.84	0.30	0.04	0.64
Revenue Estimate	341.31M	303.40M	316.79M	297.65M
Revenue Actual	378.20M	310.60M	312.00M	296.00M

To track all earnings releases for Neurocrine Biosciences visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.